News

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $36.17, moving 5.51% from the previous trading session.

Hims & Hers Health has delivered a very large 3 year return, yet the stock still screens as undervalued on market multiples while only scoring weakly on broader valuation checks. A roughly 344.6% return over 3 years puts Hims & Hers Health among the stronger performers in digital health, which raises the bar for what future growth and execution need to justify. Recent traction in branded GLP-1 and peptide related offerings can support optimistic revenue expectations, but evolving FDA...

One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

CEO Andrew Dudum said Hims treats 10,000 to 15,000 patients daily and aims to become the healthcare industry’s “gold standard.”

Peptides are short-chain amino acids that are formulated into drugs. Insulin is a peptide. Legions of other peptides are on the market in the “wellness” industry, promoted for everything from athletic performance to skin care, mental focus, and “romantic connection”—the latter pitched by a startup called Feel Peptides.

The uncommitted facility provides Hims with a working-capital tool as it scales its healthcare and pharmacy operations.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and t

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

The FDA staff’s view clashes with RFK Jr.’s push to deregulate peptides and move more of them toward Category 1 status.

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from the previous trading day.

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Hims had 2.6 million subscribers in Q1, up 9% year over year, with Q2 expected to show how much the Novo deal is helping demand.

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best weight loss drugs on this list. TheFly reported on June 17 that Barclays maintained its Overweight rating on HIMS while increasing its price target to $39.00 from $29.00. The […]

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading session.

Hims & Hers Health (NYSE:HIMS) is expanding its GLP-1 weight-loss treatment offerings, adding new options to its telehealth platform. The company has entered into a partnership with Novo Nordisk to provide access to medications such as Wegovy and Ozempic. Hims & Hers Health is extending its international reach through the acquisition of Eucalyptus. Hims & Hers Health, best known for its direct-to-consumer telehealth services, is moving deeper into prescription weight management at a time...

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Dudum also expressed interest in Garmin integration, saying company teams are actively exploring the feature.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Barclays raises its target to $39 as GLP-1 momentum builds and a peptide ruling approaches

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.89, moving +1.33% from the previous trading session.

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.

Analysts and investors have turned their attention to a key regulatory meeting on peptides, a decision expected to trigger HIMS’ next phase of growth.

Hims & Hers has made clear its interest in the peptides. It owns a peptide manufacturer and said it “sees meaningful potential” in the drugs.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Investor Jonah Lupton said peptide market forecasts may be "too conservative," citing growing consumer interest.

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. Hims & Hers rallied by 12.49 percent on Monday to finish at $30.17 apiece, as investors cheered rosy growth prospects for the obesity market, alongside its efforts to bridge the gap between the rapidly increasing demand […]

In recent days, Hims & Hers Health, Inc. amended its revolving credit agreement to support the completed acquisition of Australian telehealth company Eucalyptus and appointed longevity-focused physician Dr. Anant Vinjamoori as Chief Medical Officer for the Hims brand. These steps coincide with a pivot toward branded GLP-1 weight loss drugs, including a new GLP-1-based weight loss membership aimed at longer-term patient relationships. By combining an expanded international footprint,...